Schizophrenia Market Summary
As per Market Research Future Analysis, the Schizophrenia Market was valued at USD 7.84 Billion in 2023 and is projected to grow to USD 13.41 Billion by 2032, with a CAGR of 5.49% from 2024 to 2032. Key drivers include increased mental health awareness, better insurance coverage, and advancements in therapies. The market is characterized by a high unmet demand for effective treatments, leading to significant R&D investments. Notable developments include Delpor, Inc.'s DLP-114 clinical trial results and Karuna Therapeutics' NDA acceptance for KarXT, indicating a focus on innovative treatment options.
Key Market Trends & Highlights
The Schizophrenia market is witnessing significant growth driven by various factors.
- Market Size in 2023: USD 7.84 Billion; projected to reach USD 13.41 Billion by 2032.
- CAGR from 2024 to 2032: 5.49%; driven by advancements in technology and therapies.
- Majority market share held by paranoid schizophrenia segment in 2022; high prevalence noted.
- Injectables segment projected to be the fastest-growing during 2024-2032 due to reduced relapse risks.
Market Size & Forecast
2023 Market Size | USD 7.84 Billion |
2024 Market Size | USD 8.29 Billion |
2032 Market Size | USD 13.41 Billion |
CAGR (2024-2032) | 5.49% |
Major Players
Johnson & Johnson, Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals, AstraZeneca, Eli Lilly, Alkermes, Sumitomo Dainippon Pharma, Pfizer.